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Abstract
Introduction: Critically ill ICU patients commonly develop severe muscle wasting and impaired muscle function,
leading to delayed recovery, with subsequent increased morbidity and financial costs, and decreased quality of life
for survivors. Critical illness myopathy (CIM) is a frequently observed neuromuscular disorder in ICU patients. Sepsis,
systemic corticosteroid hormone treatment and post-synaptic neuromuscular blockade have been forwarded as the
dominating triggering factors. Recent experimental results from our group using a unique experimental rat ICU
model show that the mechanical silencing associated with CIM is the primary triggering factor. This study aims to
unravel the mechanisms underlying CIM, and to evaluate the effects of a specific intervention aiming at reducing
mechanical silencing in sedated and mechanically ventilated ICU patients.
Methods: Muscle gene/protein expression, post-translational modifications (PTMs), muscle membrane excitability,
muscle mass measurements, and contractile properties at the single muscle fiber level were explored in seven
deeply sedated and mechanically ventilated ICU patients (not exposed to systemic corticosteroid hormone
treatment, post-synaptic neuromuscular blockade or sepsis) subjected to unilateral passive mechanical loading for
10 hours per day (2.5 hours, four times) for 9 ± 1 days.
Results: These patients developed a phenotype considered pathognomonic of CIM; that is, severe muscle wasting
and a preferential myosin loss (P < 0.001). In addition, myosin PTMs specific to the ICU condition were observed in
parallel with an increased sarcolemmal expression and cytoplasmic translocation of neuronal nitric oxide synthase.
Passive mechanical loading for 9 ± 1 days resulted in a 35% higher specific force (P < 0.001) compared with the
unloaded leg, although it was not sufficient to prevent the loss of muscle mass.
Conclusion: Mechanical silencing is suggested to be a primary mechanism underlying CIM; that is, triggering the
myosin loss, muscle wasting and myosin PTMs. The higher neuronal nitric oxide synthase expression found in the
ICU patients and its cytoplasmic translocation are forwarded as a probable mechanism underlying these
modifications. The positive effect of passive loading on muscle fiber function strongly supports the importance of
early physical therapy and mobilization in deeply sedated and mechanically ventilated ICU patients.
Introduction
The mortality rate has typically been the primary out-
come considered in reports on critically ill ICU patients
[1,2]. Recent advances in ICU care have significantly
improved the survival rate of critically ill ICU patients.
However, modern critical care also needs to address
post-ICU complications and long-term quality of life.
Several recent studies have reported a severely impaired
quality of life in critical illness survivors several years
after ICU and hospital discharge, primarily due to an
impaired neuromuscular function [1,3,4].
During ICU treatment, a large proportion of the criti-
cally ill, mechanically ventilated ICU patients develop
severe muscle wasting and weakness of limb muscles
due to acquired myopathy, neuropathy or a combination
of both. Acquired myopathy is by far the most common
cause underlying this specific muscle weakness, but is
frequently misdiagnosed due to insufficient diagnostic
criteria or methodological limitations [5,6]. This
* Correspondence: lars.larsson@neuro.uu.se
† Contributed equally
1Department of Neuroscience, Clinical Neurophysiology, Uppsala University,
Entrance 85, Uppsala University Hospital, Uppsala 751 85, Sweden
Full list of author information is available at the end of the article
Llano-Diez et al. Critical Care 2012, 16:R209
http://ccforum.com/content/16/R209
© 2012 Llano-Diez et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
myopathy, characterized by reduced muscle membrane
excitability and a preferential loss of the molecular
motor protein myosin, has been given multiple different
names, the most common being acute quadriplegic
myopathy or critical illness myopathy (CIM). Primary
disease, sepsis and multiorgan failure undoubtedly con-
tribute to the impaired muscle function, but there is
heterogeneity of underlying disease and pharmacological
treatment among patients with similar outcomes. The
common components of ICU treatment per se - such as
bed rest, muscle unloading, mechanical ventilation, and
sedation - are thus probably all directly involved in the
progressive impairment of muscle function during long-
term ICU treatment.
Using a unique experimental ICU model allowing
detailed studies of skeletal muscle in mechanically venti-
lated, deeply sedated, pharmacologically paralyzed and
extensively monitored rats for several weeks [7], we have
recently shown that the complete mechanical silencing
associated with the ICU condition (absence of external
strain related to weight-bearing, and internal strain in the
muscle fiber caused by myosin-actin activation) induces a
phenotype identical to the acquired myopathy in ICU
patients with CIM [8]. Mechanical silencing has accord-
ingly been forwarded as an important etiological factor
underlying this specific myopathy [8].
The ability of the muscle cell to sense, process, and
respond to mechanical stimuli is an important regulator
of gene expression and protein synthesis and is therefore
an important regulator of physiological and pathophy-
siological function, an interplay sometimes referred to as
tensegrity [9-13]. In a clinical study, Griffiths and cow-
orkers demonstrated that unilateral continuous passive
movement for 3 hours three times per day during 7
days preserved the architecture of the muscle fiber and
protein loss in five mechanically ventilated, pharmacolo-
gically paralyzed and critically ill ICU patients [14].
Furthermore, a number of different recent studies have
shown that early intense physical therapy in ICU
patients significantly shortens the ICU and hospital
stays, reduces healthcare costs and improves overall
patient quality of life [15-18]. These encouraging results
have the potential to induce a paradigm shift in atti-
tudes towards physiotherapy and the prevention of ICU
muscle wasting and weakness. However, the mechan-
isms underlying intervention effects on skeletal muscle
structure and function in immobilized ICU patients
remain unknown.
This study aims to unravel the mechanisms underlying
the muscle atrophy seen in deeply sedated and mechani-
cally ventilated ICU patients and how these mechanisms
can be affected by passive mechanical loading. Muscle
gene/protein expression, post-translational contractile
protein modifications, muscle membrane excitability and
regulation of muscle contraction at the cellular level
were explored after unilateral passive standardized
mechanical loading of ankle joint flexors and extensors
for 10 hours per day (2.5 hours, four times per day) for
9 ± 1 days (7 to 11 days). The cross-sectional area
(CSA) of the tibialis anterior (TA) muscle and electro-
physiological properties of the muscle and peripheral
motor nerves were monitored during the observation
period. At the end of the observation period, percuta-
neous muscle biopsies were taken from both the loaded
and unloaded TA muscle and were analyzed for gene/
protein expression, post-translational modifications
(PTMs) and regulation of muscle contraction at the sin-
gle muscle cell level.
The purpose of this study was to better understand
the mechanisms underlying CIM, and to evaluate the
effects of passive mechanical loading on muscle struc-
ture and function in sedated and mechanically ventilated
ICU patients. We hypothesized that mechanical silen-
cing is a dominant factor triggering the muscle wasting
and weakness associated with CIM in ICU patients, and
that the passive mechanical loading alleviates the muscle
wasting, the preferential myosin loss and the loss in spe-
cific force (maximum force normalized to muscle fiber
CSA). The results from this study confirm that the ICU
intervention per se (immobilization, sedation and
mechanical ventilation) plays a critical role in the prefer-
ential myosin loss, a major diagnostic feature of CIM
Materials and methods
Patients and control subjects
A total of seven mechanically ventilated ICU patients
(four females and three males, aged 56 to 67 years)
numbered M1 to M7 were included in this study. The
clinical history and medications used by each patient are
summarized in Table 1. Patients anticipated to require
mechanical ventilation for 10 consecutive days or longer
were recruited. Patients had typically been exposed to
mechanical ventilation and immobilization for 0 to 3
days (1.7 ± 0.9 days) prior to initiating the intervention
and monitoring due to delays related to obtaining signed
informed consents. Patients with a previous history of
neuromuscular disease were not included in the study.
There was no evidence of severe sepsis (sepsis with
organ dysfunction) in any of the patients according to
the 2001 SCCM/ESIMC/ACCP/ATS/SIS International
Sepsis Definitions Conference. None of the patients
received systemic administration of neuromuscular
blocking agents, and only one patient (M1) received
administration of inhaled corticosteroids (daily dose: 1
mg) due to asthma. Propofol was intravenously adminis-
tered in all patients.
Written informed consent was obtained from patients’
close relatives prior to beginning the study. This study was
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approved by the local Ethical Committee on Human
Research at Uppsala University Hospital, Uppsala, Sweden.
Muscle biopsies were obtained from the TA muscle
on both the unloaded and loaded sides using the percu-
taneous conchotome method on the final day of the
observation period. Muscle biopsies were not taken at
the start of the intervention in order to eliminate the
risk of the first biopsy sampling procedure interfering
with the results from the biopsy obtained at the end of
the observation period. Each biopsy was dissected and
treated as previously described [19]. For details, please
see Additional file 1.
Muscle biopsies from the TA muscle from a total of
eight healthy control subjects (seven females and one
male, age 67 to 78 years) were included for quantitative
RT-PCR and myosin:actin protein ratio comparisons. All
muscle samples from patients and controls were
obtained. A total of 40 healthy control male and female
subjects (aged 23 to 75 years) were included as reference
material for the comparison of the compound muscle
action potential (CMAP) amplitude during direct and
indirect (nervus fibularis) TA muscle stimulation.
For comparison of mass-spectrometry protein PTMs,
13 healthy male control subjects (aged 25 to 89 years)
were included for analysis of type I and type IIa myosin
heavy chain (MyHC) isoforms from limb muscles (vas-
tus lateralis).
Mechanical loading
Ankle joint flexors and extensors were passively loaded
for 2.5 hours four times per day during 7 to 11 days (9
± 1 days) using a Kinetec™ Breva™ Ankle CMP
machine (A Patterson Medical Company, Tournes,
France); that is, continuous passive anatomically correct
motion from 30° plantar flexion to 25° dorsiflexion was
generated at a speed corresponding to 150°/minute.
Ultrasound measurements
The left and right TA CSAs were measured every day
during the intervention period (7 to 11 days) using a
real-time ultrasound scanner (Siemens Acuson Antares
Ultrasound System, Mountain View, CA, USA) with a 9
to 4 MHz linear array transducer. The principles of ultra-
sound scanning have been described previously [20].
Scans were taken transversally on relaxed muscles at
three locations: 50%, 40% and 30% of the distance from
the proximal part of the fibula head to the distal tip of
the lateral malleolus. These distances were marked on
the skin with a marker pen to eliminate intra-individual
variations in the location of measurements during the
observation period. Ultrasound coupling gel (Polaris II;
GE Medical Systems, Aulnay sous Bois, France) was
applied to the skin and transducer head. The transducer
was placed at the different locations and held perpendi-
cular to the skin to ensure a clear image and perpendicu-
lar to the direction of TA muscle to acquire transverse
measurements. The captured muscle images were stored,
the region of interest (TA muscle mass without bone and
fascia) was manually selected and the CSA was measured
using a SieScape™ panoramic imaging processor (Sie-
mens AG, Erlangen, Germany).
The mean CSA was calculated as the mean of three
consecutive measurements at the three different locations
(50%, 40% and 30%) on each leg. Coefficients of varia-
tions were calculated from the two initial CSA measure-
ments at each location and from the average of all three
locations combined. Coefficients of variation were <5%
for all measurements and on average were 1.77% for
Table 1 Clinical history and medications used by each ICU patient
Patient Age
(years)




Primary disease History Pharmacology SAPS
II







M2 62 M 2 9 Acute subdural
hematoma
Hypertony, alcoholic Antibiotics 50
M3 67 M 2 8 Subarachnoid
hemorrhage
Hypertony Antibiotics 41










M6 59 F 1 11 Cerebellar
hemorrhage
Antibiotics 34
M7 62 M 2 7 Bilateral cerebellar
infarction
Antibiotics 42
COPD, chronic obstructive pulmonary disease; F, female; M, male; SAPS, Simplified Acute Physiology Score. aAfter the intervention started.
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measurement at each single location and 1.04% when
taking the mean of the three different locations.
Electrophysiological measurements
Motor (nervus fibularis, and tibialis) and sensory (nervus
suralis and fibularis superficialis) nerves were measured
bilaterally (Keypoint Medtronic, Skovlunde, Denmark)
using a surface electrode both for stimulation and
recording. Studies were performed on the first and final
days of the observation period in all patients, and two of
the seven patients (M6 and M7) were monitored every
second day during the observation period. Nerve con-
duction velocities were compared with reference values
from age-matched and height-matched control subjects
(Department of Clinical Neurophysiology, Uppsala Uni-
versity Hospital). The CMAP amplitudes upon supra-
maximal motor nerve stimulation were measured from
the musculus extensor digitorum brevis (nervus fibularis
stimulation) and musculus abductor hallucis (nervus
tibilalis stimulation). On the final day of the period, con-
centric needle electromyography was performed in the
musculus vastus lateralis and tibialis anterior bilaterally
(Keypoint Medtronic).
The CMAP amplitude was measured upon direct
supramaximal musculus tibialis anterior stimulation
(dmCMAP) and compared with the CMAP amplitude in
response to supramaximal nervus fibularis stimulation
(neCMAP) bilaterally on the final day of the observation
period. CMAP amplitudes were measured peak to peak.
neCMAP was measured in response to supramaximal
stimulation of nervus fibularis at the level of the fibular
head and recording electrodes were kept in the same
position as during the dmCMAP measurement. The
neCMAP:dmCMAP amplitude ratio was calculated. The
limb skin temperature was kept at >32°C. Filter settings
were 2 Hz to 5 KHz and the stimulus duration was 0.1
ms (1 Hz stimulation rate). For details, please see Addi-
tional file 1.
Contractile measurements of single muscle fibers
Single muscle fiber experiments were performed as
described previously [8]. In brief, a fiber segment 1 to 2
mm long was attached to a force transducer (model 400
A; Aurora Scientific, Aurora, ON, Canada) and a lever
arm system (model 308B; Aurora Scientific). While the
fiber segments were in relaxing solution, the sarcomere
length was set at 2.65 to 2.75 μm by adjusting the over-
all segment length [21] and the resting tension was
assessed. The fiber was then moved to activating solu-
tion (pCa 4.5) in which all the recordings were per-
formed. The focusing control of the microscope was
used as a micrometer. Fiber CSA was calculated from
the diameter and depth, assuming an elliptical circum-
ference, and was corrected for the 20% swelling that is
known to occur during skinning [22]. Because single
muscle fibers expressing the type II MyHC isoform were
absent in several patients, CSA and force measurements
were restricted to muscle fibers expressing the type I
MyHC isoform.
Enzyme histochemistry and immunocytochemistry
Cross-sections (10 μm) were cut perpendicular to the
longitudinal axis of muscle fibers with a cryostat (2800
Frigocut E; Reichert-Jung GmBH, Heidelberg, Germany)
at -20°C. The sections were stained for NADH (3.2 mg
Nicotinamide adenine dinucleotide, 8.0 mg Nitro blue
tetrazolium, 2.0 ml 3-(N-Morpholino)propanesulfonic
acid solution, 8.0 ml distilled H2O).
Muscle fiber CSA measurements were restricted to
type I fibers since type II fibers were absent in some of
the patients. Type I fiber CSA was measured for 50
fibers in the central region of the biopsy cross-section
and measured using an inverted microscope (Axiovert
40 CFL; Carl Zeiss, Jena, Germany) and imaging soft-
ware (Compix Simple PCI 6; Compix Inc., Sewickley,
PA, USA).
Neuronal nitric oxide synthase (nNOS) expression was
assessed on 10 μm TA cryo-sections from patients and
healthy controls. Sections were blocked using Back-
ground sniper (Histolab, Göteborg, Sweden).
Primary antibodies were rabbit anti-nNOS (Invitrogen,
Carlsbad, CA, USA) and rat anti-Laminin gamma 1 (Milli-
pore, Billerica, MA, USA). Secondary antibodies were anti-
rabbit Cy3 donkey and anti-rat Dylight 488 goat conju-
gates (BioLegend, San Diego, CA, USA). Nuclei were
visualized with 4’,6-diamidino-2-phenylindole. All samples
were stained with identical primary and secondary anti-
body dilutions and immunofluorescence was analyzed by
confocal microscopy (LSM510 Meta; Zeiss).
Myosin:actin protein ratio
TA 10-μm cryo-sections were dissolved in 100 μl urea
buffer (8 M; 120 g urea, 38 g thiourea, 70 ml H2O, 25 g
mixed bed resin, 2.89 dithiothreitol, 1.51 g Trizma base,
7.5 g SDS) after centrifugation and heating (90°C for 2
minutes). The total protein content of the samples was
measured with Pierce® 660 Protein assay (ThermoFisher
Scientific Inc., Rockford, IL, USA) according to the
manufacturer’s instructions. The samples were run on
12% SDS-PAGE and gel bands corresponding to actin
and myosin were identified and quantified as previously
described [8]. These values were used to determine
myosin:actin protein ratios.
Post-translational modifications
Cross-sections from TA from ICU patients and vastus
lateralis from controls were run on 6% SDS-PAGE gel.
Gel bands corresponded to myosin heavy chain I and
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IIa. Samples were digested in gel, separated with 40-
minute gradient RP-nanoHPLC and analyzed online
using a 7-Tesla LTQ-FT Ultra tandem mass spectro-
meter (ThermoFisher Scientific Inc.) modified with a
nano electrospray ion source (ProxeonBiosystems, Ther-
moFisher Scientific Inc.). A high-resolution survey scan
followed by low-resolved mass spectrometry/mass spec-
trometry scans of the five most abundant peaks were
used. Peptide identification was performed using the
Mascot search engine, allowing two missed cleavages
and a set of variable post-translational modifications
(that is, multiple oxidations, methylations, and phos-
phorylations). The myosin modeling used in the study
has been described extensively elsewhere [23] and was
visualized with UCSF Chimera [24]. For detailed infor-
mation, please see Additional file 1.
Quantitative real-time PCR
Quantitative RT-PCR was used to quantify the mRNA
levels for human type I MyHC, type IIa MyHC, skeletal




Total RNA was extracted from frozen TA samples and
then quantified as previously described [5]. Then 100 ng
total RNA from TA samples were reverse transcribed to
cDNA using Qscript cDNA supermix (Quanta Bios-
ciences, Gaithersburg, MD, USA). cDNA was amplified
in triplicate using the MyiQ™ single-color real-time
PCR detection system (Bio-Rad Laboratories, Inc., Her-
cules, CA, USA). For details regarding the PCR protocol
and primers used, please refer to Additional file 1.
Statistical analysis
SigmaPlot software (Systat Software, Inc., San Jose, CA,
USA) was used to generate descriptive statistics. Means,
standard errors of the means and linear regression analy-
sis were calculated according to standard procedures. A
paired t test was used in pairwise comparisons between
unloaded and loaded legs. One-way analysis of variance
and the Tukey post-hoc test were used when comparing
multiple groups. When the normality test failed, a one-
way analysis of variance on ranks (that is, Kruskal-Wallis
test) and the Dunn’s post-hoc test were performed. Dif-
ferences were considered significant at P < 0.05.
Results
ICU patients
This study was carried out in seven mechanically venti-
lated ICU patients between 7 and 11 days (9 ± 1 days).
All subjects were adults (62 ± 1 years). Patient charac-
teristics are summarized in Table 1 along with their pri-
mary diagnosis, medications used, biopsy time and days
of exposure to mechanical ventilation prior to starting
the intervention. None of the patients had a history of
neuromuscular disorders. No spontaneous movements
in the deeply sedated patients were recorded during the
observation period. Average body weight decreased (P <
0.05) from 79.9 ± 5.5 to 78.3 ± 5.4 kg at the end of the
observation period.
Ultrasound measurements
A linear decline was observed in TA CSA during the
observation period on both the loaded side (r2 = 0.999,
P < 0.001) and the unloaded side (r2 = 0.991, P < 0.001)
(Figure 1A). On the final day of the observation period,
TA CSA had declined by 21 ± 1% and there was no dif-
ference in TA CSA between the loaded and unloaded
legs (Figure 1B). The results thus demonstrate a decline
in TA CSA proportional to the length of the ICU stay,
but mechanical loading did not influence the overall TA
muscle CSA.
Electrophysiological measurements
Motor and sensory nerve conduction velocities and
amplitudes were not affected during the observation
period (Table 2). However, mild pathological findings
were recorded in some of the patients at the first exami-
nation; that is, three patients had lower than normal
neCMAP, and one patient with diabetes mellitus (M6)
had a sensory neuropathy (low sural nerve action poten-
tial amplitudes and absent nervus fibularis superficialis
responses). Further, two patients developed a mild con-
duction block of the nervus fibularis at the fibula head
region at the end of the observation period. On the final
day of the intervention, no pathological spontaneous
electromyography activity had occurred in any of the
legs. The neCMAP:dmCMAP ratio was normal (>0.75)
in all fully sedated and mechanically ventilated patients,
except in two patients with conduction block where the
ratios were 0.25 and 0.26.
Single muscle fiber properties
The CSA and force generation capacity (maximum force
normalized to muscle fiber CSA; that is, specific force)
were measured in single muscle fibers obtained from
TA muscle biopsies from both the loaded and unloaded
sides on the final day of the observation period. The TA
muscle in humans is dominated by fibers expressing the
type I MyHC isoform, and type IIa MyHC fibers were
scarce and not observed in all patients. Analyses have
therefore been restricted to muscle fibers expressing the
b/slow (type I) MyHC isoform.
A total of 140 TA muscle fibers passed the acceptance
criteria (see Materials and methods) and were included
in the analyses. The specific force was higher (P < 0.05
to 0.001) in muscle fibers on the loaded side than on
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the unloaded side in five out of the seven patients
(Figure 2). A similar trend was observed in the other
two patients (M2 and M6), but failed to reach statistical
significance. Overall, 9 ± 1 days of passive mechanical
loading resulted in a 35% higher specific force (P <
0.001) compared with the unloaded leg. The CSA mea-
sured at a fixed sarcomere length in single muscle fibers
expressing the type I MyHC isoform did not differ
between the loaded side (2,260 ± 140 μm2) and the
unloaded side (2,250 ± 120 μm2). Similar results were
obtained from morphometrical measurements of
NADH-stained muscle TA muscle cross-sections; that
is, the size of the slow-oxidative (type I) muscle fibers
did not differ between the loaded leg (3,570 ± 90 μm2)
and the unloaded leg (3,640 ± 100 μm2). Muscle fiber
size measurements are thus in agreement with ultra-
sound measurements demonstrating similar TA muscle
size on the loaded and unloaded sides.
Myosin:actin protein ratio
In both the unloaded and loaded legs, the myosin:actin
ratio was significantly lower (P < 0.001) in patients com-
pared with muscle biopsies from healthy control indivi-
duals (Figure 3). Although there was a slight tendency
towards a higher myosin:actin ratio on the loaded side,
this difference was not statistically significant.
Post-translational myosin modifications
A mass spectrometry approach was taken to determine
myosin PTMs in response to the ICU condition per se
Days













































Figure 1 Ultrasound measurements of tibialis anterior cross-sectional area. (A) Relative cross-sectional area (CSA) during the intervention
period (9 ± 1 days). Solid line, loaded side; dashed line, unloaded side. Values are mean ± standard error of the mean (SEM). The value at day 1
is equivalent to 100%. (B) Relative CSA decline in the loaded leg (black bars) and the unloaded leg (white bars) for each ICU patient on the final
day of the intervention, and mean ± SEM for all patients.
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Table 2 Electrophysiological observations
Day 1 Day 9 ± 1
Unloaded leg Loaded leg P value Unloaded leg Loaded leg P value
Motor
Fibularis
Amplitude (mV) 4.7 ± 0.8 4.1 ± 0.6 NS 4.0 ± 1.1 3.6 ± 0.7 NS
CV (m/second) 45.8 ± 2.5 46.6 ± 1.9 NS 45.6 ± 2.9 42.6 ± 2.2 NS
Latency (milliseconds) 4.5 ± 0.3 4.5 ± 0.4 NS 4.0 ± 0.3 4.6 ± 0.5 NS
F-response (milliseconds) 37.0 ± 3.4 26.4 ± 9.4 NS 32.1 ± 10.2 42.9 ± 8.7 NS
Tibialis
Amplitude (mV) 7.6 ± 0.9 7.8 ± 0.9 NS 9.6 ± 1.5 9.5 ± 1.4 NS
CV (m/second) 44.7 ± 1.0 47.3 ± 2.5 NS 44.4 ± 1.6 45.6 ± 2.2 NS
Latency (milliseconds) 4.0 ± 0.3 4.4 ± 0.3 NS 3.7 ± 0.2 4.0 ± 0.3 NS
F-response (milliseconds) 49.2 ± 1.6 50 ± 1.4 NS 49.1 ± 1.8 42.5 ± 8.6 NS
Sensory
Suralis
Amplitude (mV) 11.7 ± 3.5 8.3 ± 1.6 NS 10.8 ± 2.9 8.3 ± 1.3 NS
CV (m/second) 51.9 ± 3.4 49.7 ± 3.3 NS 50.8 ± 2.1 38.4 ± 8.2 NS
Fiburalis superficialis
Amplitude (mV) 4.6 ± 1.3 6.1 ± 1.6 NS 6.5 ± 2.9 7.0 ± 1.8 NS
CV (m/second) 40.5 ± 7.2 40.6 ± 7.1 NS 45.5 ± 8.6 40.6 ± 7.0 NS
DMS (neCMAP:dmCMAP ratio) 1.1 ± 0.1 1.4 ± 0.3 NS
Data presented as mean ± standard error of the mean. CV, coefficient of variation; dmCMAP, compound muscle action potential upon direct muscle stimulation;




























Figure 2 Specific force in single muscle fibers. Specific force in single muscle fibers expressing the type I myosin heavy chain isoform in the
loaded and unloaded legs from patients exposed to unilateral loading and mechanical ventilation for 9 ± 1 days. Black circles, individual means;
open triangles, average for all patients pooled together ± standard error of the mean.
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as well as the effect of the passive mechanical loading.
Type I and type IIa MyHC isoforms were separated on
6% SDS-PAGE gels extracted and screened for acetyla-
tion, carboxylation, deamidation, glucosylation, methyla-
tion, nitration, ubiquitination, and phosphorylation by
liquid chromatography-mass spectrometry.
Myosin modifications specific for the ICU condition
were observed when comparing patients’ samples with
healthy controls (Table 3). Four modifications not
observed in the controls were detected in the ICU
patients; two of these modifications were observed in all
seven patients and two PTMs were observed in six of
Patients




























Figure 3 Myosin:actin protein ratios in unloaded and loaded legs. Myosin:actin protein ratios in tibialis anterior muscle cross-sections from
each mechanically ventilated ICU patient in the unloaded leg (white bars) and the loaded leg (black bars), and from healthy controls (hashed
bar). Mean ± standard error of the mean given for patients in the loaded and unloaded legs as well as in healthy controls. ***Statistically
significant differences versus the healthy control group (P < 0.001).
Table 3 Post-translational modifications specific to ICU patients
Modification type Peptide sequence Amino acid modified Frequency Position
New
Deamidation ENQSILITGESGAGK Q 12/14 173
Deamidation SVNDLTSQR N 10/14 1,271
Deamidation GQTVEQVSNAVGALAK N 11/14 425
Methylation INQTLDTK D 10/14 451
Lost
Acetylation ASLLAAELEELR S 2/14 1,686
Carbonylation AGLLGLLEEMRDER R 0/14 780
Carbonylation AGLLGLLEEMRDER D 1/14 781
Carbonylation LQNEIEDLMVDVER D 0/14 1,427
Carbonylation NLTEEMAGLDETIAK D 1/14 992
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the seven patients. Three PTMs were identified in the
motor domain (deamidation amino acids 173 and 425,
methylation amino acid 451) and one in the tail region
(deamidation amino acid 1,271) (Figure 4). One modifica-
tion was unique for the type I MyHC isoform (deamida-
tion amino acid 1,271) and the other three modifications
were observed in both type I and type IIa myosin iso-
forms. Further, five modifications were lost in the ICU
patients, and all were in the tail region (acetylation amino
acid 1,686 and carbonylation amino acids 780, 781, 992
and 1,427). No specific myosin PTMs were observed in
response to the passive loading.
Neuronal nitric oxide synthase expression
The expression of nNOS was analyzed by immunocyto-
chemistry and basal expression was low and restricted
to the sarcolemma in controls (Figure 5). In the ICU
patients, a significantly higher nNOS expression was
observed in the sarcolemma region (Figure 5). In addi-
tion, nNOS shuttling from the sarcolemma to the cyto-
plasm was observed at the end of the observation period
in all ICU patients. A similar nNOS upregulation and
shuttling has been reported in muscle atrophy in
response muscle unloading during hind limb suspension
[25] and in patients with amyotrophic lateral sclerosis
[26]. No differences in nNOS expression or localization
were observed in response to passive loading (Figure 5).
Quantitative real-time PCR
Long-term immobilization and mechanical ventilation
resulted in a dramatic downregulation (P < 0.05 to
0.001) of the dominating thick and thin filament pro-
teins in the human TA; that is, type I and type IIa
MyHCs and actin (Figure 6). Expression of the most
abundant thick filament protein in the TA muscle after
myosin, the slow isoform of MyBP-C, was lower but not
statistically significant, and the MyBP-H expression was
higher (P < 0.05) in the ICU patients compared with
healthy controls. The expression of these genes did not
differ significantly between the loaded leg and the
unloaded leg (Figure 6).
Discussion
The results from this study show that 7 to 11 days of the
ICU condition resulted in a muscle phenotype suggested
to be pathognomonic of the severe acquired myopathy
(acute quadriplegic myopathy or CIM) observed in ICU
patients; that is, a preferential myosin loss. Further, this
phenotype was observed in the absence of triggering fac-
tors suggested to play an important role in the develop-
ment of this myopathy, such as systemic corticosteroid
hormone administration, sepsis and neuromuscular block-
ade. The mechanical silencing is accordingly suggested to
be an important factor triggering CIM in ICU patients
with or without other triggering factors such as sepsis and
systemic corticosteroid hormone treatment. Furthermore,
passive mechanical loading applied for 2.5 hours four
times per day for 9 ± 1 days in immobilized, sedated and
mechanically ventilated ICU patients improved the muscle
fiber function by 35% without affecting muscle mass.
These results demonstrate an important beneficial effect
of passive loading on muscle function and strongly sup-
port active physical therapy as an important early inter-
vention strategy in immobilized ICU patients in spite of
the fact that it did not alleviate the muscle wasting asso-
ciated with the ICU condition; that is, mechanical ventila-
tion, sedation and immobilization.
Preferential myosin loss
CIM is a common acquired myopathy in ICU patients and
up to 42% of the ICU population may develop CIM [27].
Awareness of this condition has increased significantly in
the past decade [28], but many patients with CIM still fail
to receive a correct diagnosis and are being misdiagnosed
as neuropathies. There is no specific treatment to date
besides reducing or eliminating causative factors, and
future intervention strategies need to be specific for the
underlying mechanism. The poor understanding of basic
mechanisms underlying CIM in the clinical setting is in
part due to the basic distinctions between acquired myo-
pathy and neuropathy often not being clearly made. Diag-
nosis and classification have frequently been based on
clinical observations and electrophysiological measure-
ments, but both are weak diagnostic indicators [6,29].
However, correct distinction between myopathy and neu-
ropathy in the ICU is very important because prognosis
differs significantly between the acquired neuropathy and
myopathy.
A preferential loss of myosin and myosin-associated
proteins has been repeatedly documented in patients
with CIM using electron microscopy, electrophoretic
separation of myofibrillar proteins, enzyme-cytochemis-
try and immuno-cytochemistry [6,30-32]. Widespread
myosin loss is therefore considered to be essentially
pathognomonic of CIM although myosin loss has been
reported in other disorders, such as dermatomyositis
[33] and cancer cachexia [34]. During the past 15 years
we have routinely measured the proportion of myosin in
relation to actin in 10 μm percutaneous muscle biopsy
cross-sections together with electrophysiological meth-
ods in the diagnosis of acquired myopathy and neuropa-
thy in ICU patients [5,29]. In our experience, the
myosin:actin ratio is the most sensitive diagnostic tool
available to detect CIM in ICU patients, being superior
to electrophysiological methods or electron microscopic,
enzyme-histochemical and immunocytochemical ana-
lyses of muscle biopsy cross-sections [6]. In this study,
all mechanically ventilated, sedated and immobilized
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Figure 4 Post-translational modifications of the myosin motor domain. (A) Ribbon diagram of the myosin motor domain (red) and part of
the tail region (blue). Three ICU-condition-specific post-translational modifications (PTMs) were observed in the motor domain of the protein
(yellow) and one lost modification was in the tail region (green). Since only part of the myosin protein is modeled, PTMs located further down
on the tail region are not shown. (B) Upper panel, spectrum of deamidated peptide ENQSILITGESGAGK; bottom panel, spectrum of intact
peptide ENQSILITGESGAGK. The deamidation is safely determined by high-resolution mass spectrometry (MS) in MS mode (the mass difference
between the molecular ion masses is 0.984 Da, corresponding to N+H-O) and in MS/MS mode as well. In the MS/MS spectrum one can see the
mass shift of +1 Da for all b-ion series, including those that correspond to neutral losses from b-ions, except b2. Since b2 ion has the same mass
for both peptides and contains asparagine, the deamidation is assigned to glutamine Gln3 and not Asn2.
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ICU patients had lower than normal myosin:actin ratios.
This is consistent with our previous studies using a rat
experimental ICU model; that is, a preferential myosin
loss in both fast-twitch or slow-twitch muscles and fiber
types was observed in response to mechanical ventila-
tion, sedation and immobilization at durations longer
than 5 days [8,35,36].
Systemic corticosteroid hormone treatment, post-
synaptic neuromuscular blockade and sepsis have all
been suggested to be important factors triggering CIM
[33,37], although mechanically ventilated and sedated
ICU patients have been reported with CIM in the
absence of exposure to these triggering agents [38-41].
Results from this and previous experimental studies sup-
port the strong impact of mechanical silencing in trig-
gering CIM; that is, a lack of both external (weight-
bearing) and internal load (strain caused by myosin-
actin activation during contraction) in mechanically ven-
tilated and sedated ICU patients with or without
neuromuscular blockade. However, the loading induced
by the passive ankle joint flexion extensions for 10
hours per day was not sufficient to reduce the unload-
ing-induced preferential myosin loss.
The mechanisms underlying the preferential myosin
loss are complex and involve the activation of different
proteolytic pathways in a specific temporal sequence
[8,42]. However, the myosin loss is not only caused by
enhanced degradation but also by decreased synthesis,
as indicated by a significant downregulation of contrac-
tile proteins at the transcriptional level. This is consis-
tent with previous observations in patients with CIM
and in experimental ICU models [5,6,8,35,36]. The spar-
ing of the thin filament protein actin in spite of a similar
downregulation at the transcriptional level has been sug-
gested to be secondary to differences in protein turnover
rate or the upregulation of the small aB-crystalline cha-
perone protecting actin from degradation [8]. In con-
trast to other thick filament proteins, MyBP-H was
    
    
Figure 5 Cross-sections of tibialis anterior muscle stained for neuronal nitric oxide synthase, Laminin and 4’,6-diamidino-2-
phenylindol. Cross-sections of tibialis anterior muscle stained for neuronal nitric oxide synthase (nNOS; red), Laminin (green) and 4’,6-diamidino-
2-phenylindol (DAPI; blue). In control, basal expression of nNOS is low and localized to the sarcolemma. ICU conditions induce strong expression
of nNOS and dislocation of nNOS to the cytoplasm (arrowheads). Scale bar = 50 μm. The overlay image for each row is shown to the left.
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upregulated at the transcriptional level in accordance
with previous observations at the mRNA and protein
levels in patients with CIM as well as in experimental
ICU models [5,8,36]. The role of MyBP-H in the organi-
zation of myosin in the thick filament during myofibril-
logenesis [43] and for substituting mutant MyBP-C in
cardiomyopathy [44] suggest that the upregulation of
MyBP-H may represent a compensatory mechanism
aiming at maintaining thick filament integrity.
A mass-spectrometry approach was taken to examine
the effects of the ICU condition on PTMs of myosin. A
series of myosin PTMs, not identified in healthy control
subjects, was observed in response to the ICU condition.
In general, new PTMs were mainly observed in the
motor domain while lost PTMs were detected in the tail
region. Furthermore, the new PTMs were located deep
within the head domain, in regions not readily accessible
for oxidative modifications, and thus suggest the pre-
sence of acute oxidative stress. Oxidative stress-induced
modifications of muscle proteins can result in unfolding
of the targeted protein domains [45], leading to an
increased exposure of hydrophobic residues that are
prone to activate the proteasome [45,46].
Nitric oxide synthase is hypothesized to play a role in
the modifications of the motor domains since three out
of the four new PTMs were deamidations. The nitrite
anion induces protein deamidation [47] and is a meta-
bolite of the physiological messenger nitric oxide, a pro-
duct of nitric oxide synthase activity. During oxidative
stress observed in critically ill ICU patients [48-50],
nitric oxide serves as a superoxide radical scavenger
(O2
-) and forms peroxynitrite (ONO2
−). Peroxynitrite is
a reactive oxidant and nitrating agent that is tightly
regulated under physiological conditions, but it also has
detrimental effects under acute oxidative stress [51]. To
test our hypothesis, the expression and localization of
nNOS was studied in TA muscle cross-sections from
the ICU patients and healthy controls. An increased
nNOS expression and a translocation from the sarco-
lemma to the cytoplasm were observed in all ICU
Genes






























Figure 6 Myofibrillar mRNA expression. Actin, myosin heavy chain (MyHC; types I and IIa), myosin binding protein (MyBP)-H, and MyBP-Cslow
mRNA expression in the unloaded leg (white bar) and the loaded leg (black bar) from ICU patients, and in the tibialis anterior muscles from
healthy controls (hashed bar). Values are starting quantity ± standard error of the mean. Statistical significance versus healthy control group: *P <
0.05 and ***P < 0.001.
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patients, suggesting higher nitric oxide levels. Hind-limb
suspension experiments have shown that nitric oxide
levels are tied to nNOS [25], indicating that nNOS is
tightly associated with elevated levels of nitric oxide in
skeletal muscles. Furthermore, cytoplasmic nNOS locali-
zation leads to nitric oxide production and is a key com-
ponent of the mechanism underlying disuse muscle
atrophy [25]. The myosin deamidations are thus sug-
gested to be linked to the CIM-induced change in
nNOS expression and localization.
Muscle mass and function
A linear decline in TA muscle CSA was observed during
the observation period, resulting in a 22% smaller CSA at
the end of the observation period. The early and linear
decline in muscle mass in response to muscle unloading
is different from our previous experimental findings from
both porcine and rodent experimental ICU models. In
the experimental studies, muscle mass and muscle fiber
size were maintained during the initial 5 days and were
followed by rapid muscle wasting [8,52-54]. This discre-
pancy may, at least in part, be explained by background
heterogeneities in patients compared with animal models,
the delayed monitoring of muscle mass and age-related
differences in muscle wasting. In the patients, muscle
mass measurements were not initiated on the first day of
the ICU condition (as in the experimental studies)
because of a delay in obtaining written informed consent
from close relatives, and all animals in the experimental
studies were young while the age of patients ranged
between 56 and 67 years.
A similar average decline in muscle and muscle fiber
size was observed in the loaded and unloaded legs; that
is, TA muscle CSA determined by ultrasound at three
different anatomical landmarks, or muscle fiber CSA
measured at a fixed sarcomere length in single muscle
fiber segments or from enzyme-histochemically stained
muscle cross-sections. The fluid shifts reported in ICU
patients [55-57] therefore appear less likely to have
masked a loading effect on TA muscle mass. The signifi-
cant loading effect on muscle fiber size reported by Grif-
fiths and coworkers in five mechanically ventilated ICU
patients exposed to unilateral loading of ankle joint flex-
ors-extensors for 9 hours per day for 7 days [14] was not
observed in this study. In accordance with Griffiths and
coworkers, there was a large individual variability in the
loading response (Figure 1B) and a maintained muscle
fiber CSA was only observed in the three most critically
ill patients of the five patients in their study, whereas in
this study none of the patients were severely ill. Interest-
ingly, Griffiths and coworkers used the ratio of protein to
DNA as an index of muscle wasting, and they found that
it decreased similarly in both limbs, concluding that the
effects of passive stretching on prevention of muscle
wasting remain uncertain [14]. Moreover, all patients in
the study by Griffiths and coworkers required complete
neuromuscular blockade, and it cannot be ruled out that
neuromuscular blockade may facilitate the impact of the
loading intervention. This discrepancy is supported by
results from the experimental rat ICU model where uni-
lateral passive mechanical loading in neuromuscular
blockade, sedated and mechanically ventilated animals
resulted in a significant muscle mass sparing effect
(Renaud G, Llano-Diez M, Ravara B, Gorza L, Feng HZ,
Jin JP, Cacciani N, Gustafson AM, Ochala J, Corpeño R,
Hedström Y, Ford GC, Nair KS, Larsson L. 2012. Sparing
of muscle mass and function by passive loading in an
experimental intensive care unit model. J. Physiol
(Lond.). Provisionally accepted).
Results from the porcine ICU model, on the contrary,
have shown identical effects on muscle mass and func-
tion in pigs exposed to sedation and mechanical ventila-
tion alone or in combination with neuromuscular
blockade [58].
In contrast to the effects on muscle size, a consistent
positive loading-induced effect was observed on muscle
fiber force-generation capacity; that is, the specific force
was 35% higher on the loaded side than on the unloaded
side. We have made similar observations in an experi-
mental rat ICU model where functional capacity was
approximately double on the loaded side versus the
unloaded side after 14 days of unilateral passive ankle
joint flexions-extensions for 12 hours per day (Renaud
G, Llano-Diez M, Ravara B, Gorza L, Feng HZ, Jin JP,
Cacciani N, Gustafson AM, Ochala J, Corpeño R, Hed-
ström Y, Ford GC, Nair KS, Larsson L. 2012. Sparing of
muscle mass and function by passive loading in an
experimental intensive care unit model. J. Physiol
(Lond.). Provisionally accepted).
In both the present clinical study and the experimen-
tal study, a loading-related increase in specific force was
observed despite a lower than normal myosin:actin ratio.
The mechanisms underlying this unexpected finding are
not known, but are speculated to be secondary to a
loading-induced effect on the intrinsic properties of the
contractile machinery. Mass-spectrometry analyses of
myosin PTMs did not, however, show any significant
differences between loaded and unloaded muscles. This
investigation targeted myosin PTMs such as acetylation,
carboxylation, deamidation, glucosylation, methylation,
ubiquitination, and phosphorylation. Other PTMs as
well as modifications of other contractile proteins,
including thin filament proteins, undetected in this
study may be affected by the loading condition with
important consequences for regulation of muscle con-
traction [59]. There is a slow turnover of myosin in ske-
letal muscle and one cannot exclude that the initial
preferential myosin loss targets a pool of newly
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synthesized myosin or myosin destined for degradation
(that is, myosin not involved in force generation).
Electrophysiology
Motor and sensory conduction velocities, amplitude
responses and neCMAP/dmCMAP ratios were typically
within the normal range and did not change signifi-
cantly during the observation period. The muscle CIM
phenotype observed in these patients at the end of the
observation period, such as a preferential myosin loss,
downregulation of contractile proteins, and upregulation
of MyBP-H, was not accompanied by a significant
change in these electrophysiological parameters. The
sensitivity of these techniques in the early detection of
CIM may accordingly be questioned. Electrophysiologi-
cal methods are typically more sensitive in detecting
neuropathies than myopathies and there were no find-
ings indicating an acquired neuropathy during the
observation period. We have previously shown that neu-
ropathy does not induce a preferential myosin loss [6].
Conclusion
A series of novel findings observed in this study are of
importance for our understanding of the mechanisms
underlying the acquired myopathy in ICU patients and
how it is affected by passive mechanical loading. To our
knowledge, none of these findings have previously been
reported in ICU patients. First, the mechanical silencing
unique for immobilized and mechanically ventilated ICU
patients under deep sedation with or without neuromus-
cular blockade is forwarded as an important factor
underlying the preferential myosin loss; that is, a labora-
tory finding considered pathognomonic for CIM in ICU
patients. Second, a series of specific PTMs was observed
in the motor domain of myosin that may be critical for
both function and for triggering proteolysis. Further-
more, the higher nNOS expression found in the ICU
patients and its cytoplasmic translocation are probably
key factors in triggering these modifications. Third, pas-
sive mechanical loading had a significant and consistent
positive effect on the force-generating capacity of indivi-
dual muscle fibers in the loaded leg, strongly supporting
the importance of early physical therapy and mobilization
in deeply sedated and mechanically ventilated ICU
patients.
Key messages
• Mechanical silencing is a primary mechanism trigger-
ing the muscle weakness and the preferential myosin
loss associated with CIM.
• Mechanical silencing induces specific PTMs in the
motor domain of myosin.
• Increased nNOS expression as well as its dislocation
to the cytoplasm is observed in ICU patients in response
to mechanical silencing; moreover, they are forwarded as
a probable mechanism underlying the highly specific
myosin PTMs.
• Passive mechanical loading has a beneficial effect on
skeletal muscle function in sedated and mechanically
ventilated ICU patients.
Additional material
Additional file 1: a text file presenting detailed methods.
Complementary information is given about electrophysiological
measurements, post-translational modifications and quantitative real-time
PCR methods described in the paper.
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